Fasting blood glucose predicts high risk of in-stent restenosis in patients undergoing primary percutaneous coronary intervention: a cohort study

References

• Alraies MC, Darmoch F, Tummala R, et al. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9(8):640–651. doi: 10.4330/wjc.v9.i8.640.
   PubMedGoogle Scholar
• Kansakar U, Jankauskas SS, Gambardella J, et al. Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosis. Atherosclerosis. 2021;324:117–120. doi: 10.1016/j.atherosclerosis.2021.03.034.
   PubMed Web of Science ®Google Scholar
• Buccheri D, Piraino D, Andolina G, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8(10):E1150–62. doi: 10.21037/jtd.2016.10.93.
   PubMed Web of Science ®Google Scholar
• Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(4):348–372. doi: 10.1016/j.jacc.2022.05.017.
   PubMed Web of Science ®Google Scholar
• Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1):23. doi: 10.1186/s12933-022-01460-5.
   PubMedGoogle Scholar
• Bertoni AG, Krop JS, Anderson GF, et al. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25(3):471–475. doi: 10.2337/diacare.25.3.471.
   PubMed Web of Science ®Google Scholar
• Ebadi SA, Pajavand H, Asadi A, et al. Relationship of musculoskeletal diseases with microvascular and macrovascular complications in patients with diabetes in Iran. Diabetes Metab Syndr. 2021;15(6):102272. doi: 10.1016/j.dsx.2021.102272.
   PubMed Web of Science ®Google Scholar
• Tu CL, Sue SP, Hsu WH, et al. Causes of in-hospital death in patients with type 2 diabetes with microvascular and macrovascular complications in Taiwan. Int J Clin Pract. 2021;75(10):e14491. doi: 10.1111/ijcp.14491.
   PubMed Web of Science ®Google Scholar
• Aronson D. Restenosis in diabetic patients: is hyperinsulinemia the culprit? Circulation. 1996;94(11):3003–3005.
   PubMed Web of Science ®Google Scholar
• Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol. 2004;43(1):8–14. doi: 10.1016/j.jacc.2003.06.019.
   PubMed Web of Science ®Google Scholar
• Piatti P, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108(17):2074–2081. doi: 10.1161/01.CIR.0000095272.67948.17.
   PubMed Web of Science ®Google Scholar
• Zhao LP, Xu WT, Wang L, et al. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up. Coron Artery Dis. 2015;26(1):5–10. doi: 10.1097/MCA.0000000000000170.
   PubMed Web of Science ®Google Scholar
• Yao HM, Wan YD, Zhang XJ, et al. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI Centre. BMJ Open. 2014;4(8):e004892. doi: 10.1136/bmjopen-2014-004892.
   PubMed Web of Science ®Google Scholar
• Yao H, Wan Y, Zhang X, et al. Data from: long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI center. Dryad digital repository. 2014 doi: 10.5061/dryad.13d31.
   Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease [published correction appears in J am soc nephrol. J Am Soc Nephrol. 2006;17(10):2937–2944. doi: 10.1681/ASN.2006040368.
   PubMed Web of Science ®Google Scholar
• An J, Nichols GA, Qian L, et al. Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diab Res Care. 2021;9(1):e001847. doi: 10.1136/bmjdrc-2020-001847.
   PubMed Web of Science ®Google Scholar
• Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–2673. doi: 10.1016/j.jacc.2014.02.545.
   PubMed Web of Science ®Google Scholar
• Carrozza JP, Jr, Kuntz RE, Fishman RF, et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993;118(5):344–349. doi: 10.7326/0003-4819-118-5-199303010-00004.
   PubMed Web of Science ®Google Scholar
• Sobel BE. Acceleration of restenosis by diabetes: pathogenetic implications. Circulation. 2001;103(9):1185–1187. doi: 10.1161/01.cir.103.9.1185.
   PubMed Web of Science ®Google Scholar
• Süselbeck T, Latsch A, Siri H, et al. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. Am J Cardiol. 2001;88(3):243–247. doi: 10.1016/s0002-9149(01)01633-2.
   PubMed Web of Science ®Google Scholar
• Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–327. doi: 10.1161/CIRCRESAHA.118.313591.
   PubMed Web of Science ®Google Scholar
• Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011;9(1):53–62. doi: 10.1038/nrcardio.2011.132.
   PubMed Web of Science ®Google Scholar
• Qin Z, Zhou K, Li YP, et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-Centre observational cohort study. Cardiovasc Diabetol. 2019;18(1):11. doi: 10.1186/s12933-019-0819-z.
   PubMed Web of Science ®Google Scholar
• Wang JL, Qin Z, Wang ZJ, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol. 2018;15(2):137–145.
   PubMedGoogle Scholar
• Cheng G, Chang FJ, Wang Y, et al. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. Med Sci Monit. 2019;25:240–247. doi: 10.12659/MSM.908692.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu K, Chen M, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20(1):137. doi: 10.1186/s12933-021-01332-4.
   PubMed Web of Science ®Google Scholar
• Wu Y, Du L, Fan M, et al. Association between oral infections, triglyceride-glucose index, and in-stent restenosis. [published online ahead of print, 2022 Nov 2] Oral Dis. 2022. doi: 10.1111/odi.14420.
   Web of Science ®Google Scholar
• Liu C, Zhao Q, Zhao Z, et al. Correlation between estimated glucose disposal rate and in-stent restenosis following percutaneous coronary intervention in individuals with non-ST-segment elevation acute coronary syndrome. Front Endocrino. 2022;13:1033354. doi: 10.3389/fendo.2022.1033354.
   PubMed Web of Science ®Google Scholar
• Hage C, Grip L, Malmberg K, et al. The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes. Diab Vasc Dis Res. 2011;8(2):143–149. doi: 10.1177/1479164111403784.
   PubMed Web of Science ®Google Scholar
• Xue W, Ma J, Yu X, et al. Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis. BMC Cardiovasc Disord. 2022;22(1):493. doi: 10.1186/s12872-022-02923-z.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang X, Wang H, et al. Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation. Ir J Med Sci. 2020;189(3):907–915. doi: 10.1007/s11845-020-02176-9.
   PubMed Web of Science ®Google Scholar
• Peuler JD, Phare SM, Iannucci AR, et al. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens. 1996;9(2):188–192. doi: 10.1016/0895-7061(95)00393-2.
   PubMed Web of Science ®Google Scholar
• Santulli G, Wronska A, Uryu K, et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014;124(9):4102–4114. doi: 10.1172/JCI76069.
   PubMed Web of Science ®Google Scholar
• Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417–422. doi: 10.1161/01.ATV.0000199519.37089.a0.
   PubMed Web of Science ®Google Scholar